QUALITATIVE AND QUANTITATIVE COMPOSITION
- Somatuline Autogel is indicated for the treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.
- Somatuline Autogel is also indicated for the treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumors.
Each pre-filled syringe contains a supersaturated solution of lanreotide acetate for injection. White to pale yellow, translucent and viscous supersatured solution in a pre-filled syringe, ready for use.
Acromegaly: For patients on Somatuline Autogel 60 mg or 90 mg every 28 days who are well controlled the dose should be maintained, or alternatively Somatuline Autogel 120 mg may be given at increased intervals of 56 or 42 days respectively. Neuroendocrine tumours: The recommended starting dose is 60 to 120 mg administered every 28 days.
MARKETING AUTHORIZATION HOLDER